Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $16.50.

A number of equities research analysts have recently issued reports on the company. William Blair reiterated an “outperform” rating on shares of Neumora Therapeutics in a research note on Wednesday, January 15th. JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Bank of America decreased their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research note on Thursday, January 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Neumora Therapeutics in a report on Friday, January 3rd.

Institutional Trading of Neumora Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp grew its position in shares of Neumora Therapeutics by 65.3% in the 3rd quarter. State Street Corp now owns 1,790,707 shares of the company’s stock worth $23,655,000 after acquiring an additional 707,409 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Neumora Therapeutics by 54.0% during the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock worth $26,159,000 after purchasing an additional 694,385 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Neumora Therapeutics by 139.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock worth $9,224,000 after buying an additional 406,891 shares during the last quarter. Auour Investments LLC bought a new stake in shares of Neumora Therapeutics during the 3rd quarter valued at about $3,302,000. Finally, Cerity Partners LLC acquired a new stake in Neumora Therapeutics during the third quarter worth about $3,209,000. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Stock Performance

NASDAQ NMRA opened at $2.12 on Monday. Neumora Therapeutics has a one year low of $1.83 and a one year high of $21.00. The company’s 50 day moving average price is $7.55 and its 200 day moving average price is $10.72. The firm has a market capitalization of $342.51 million, a price-to-earnings ratio of -1.13 and a beta of 2.71.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same quarter last year, the firm earned ($1.14) EPS. Sell-side analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.